CD4 and myeloid sarcoma: In MS patients, intravenous methylprednisolone treatment modulates gene expression profiles of CD4+ T lymphocytes, it can also induce Treg cells expansion and reduce proinflammatory cytokine secretion, and thus alleviates MS.3